

REMARKS

According to the Examiner, the Reply filed 12/17/2008 is not fully responsive in that the species election of the VEGF inhibitor 1-(chloroanilino)-4-(4-pyridylmethyl)phthalazine along with the parenthetical (PTK787) discloses 2 separate compounds. Applicants submit that an inadvertent typographical error was made in the chemical name of the compound PTK787.

Applicants intended to elect 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, which corresponds to the compounds PTK787, as the single VEGF inhibitor which. As indicated in the 12/17/2008 Reply this compound is disclosed on page 38 of the specification

Entry of this response is requested and an action on the merits is awaited.

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7824

Date: May 7, 2008